Anivive Lifesciences Unveils Groundbreaking Research at World Vaccine Congress
NIAID Funds Animal Health Vaccine Development
Washington, D.C. - April 4, 2024
Anivive Lifesciences, a One Health technology company, has partnered with the National Institute of Allergy and Infectious Diseases (NIAID) to develop a novel vaccine for Valley Fever in dogs. The research will be presented at the upcoming World Vaccine Congress in Barcelona, Spain.
Valley Fever is a serious respiratory infection caused by the fungus Coccidioides. It is endemic to the southwestern United States and Mexico, and is a major health concern for both humans and animals. Dogs are particularly susceptible to Valley Fever, and the infection can be fatal if not treated promptly.
Anivive's vaccine is based on the company's proprietary Antigen Cartography technology. This platform allows researchers to identify and target specific antigens on the surface of the Coccidioides fungus. The vaccine is designed to stimulate the immune system to produce antibodies that can neutralize the fungus and prevent infection.
Preclinical studies have shown that the vaccine is safe and effective in dogs. The vaccine has been shown to protect dogs from infection with Valley Fever, and to reduce the severity of symptoms in infected animals. Anivive is currently conducting field trials of the vaccine in dogs, and the vaccine is expected to be available for commercial use in 2025.
The NIAID's funding will support the development of the Valley Fever vaccine, as well as other animal health vaccines based on Anivive's Antigen Cartography technology. The partnership between Anivive and NIAID is a testament to the importance of One Health research, which aims to improve the health of both humans and animals.
Comments